drugset / Trial / NCT06200168
Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer
RandomizedParallel-groupTriple-blindTreatment
Summary
This randomized controlled phase III trial aims to evaluate the use of electroacupuncture in combination with olanzapine-containing standard quadruple antiemetic drugs for the treatment of nausea and vomiting induced by highly emetogenic chemotherapy (HEC) in patients with breast cancer. Furthermore, it will analyze the relationship between single nucleotide polymorphism and electroacupuncture treatment for chemotherapy-induced nausea and vomiting.
Timeline
- Start
- 2024-01-16
- Primary completion
- 2026-10-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Aprepitant | Other / unclassified | 130 mg | Intravenous |
| Background | Fosaprepitant | Other / unclassified | 150 mg | Intravenous |
| Background | Olanzapine | Small molecule | 2.5 mg | Oral |
| Background | Palonosetron | Other / unclassified | 0.25 mg | Intravenous |
Indications
No indication recorded.